Worth Venture Partners, LLC Biomarin Pharmaceutical Inc Transaction History

Worth Venture Partners, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$87.74 - $117.27 $284,189 - $379,837	3,239 New	3,239 $314,000
Q2 2021 Aug 16, 2021	SELL	$75.51 - $84.79 $514,978 - $578,267	-6,820 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$74.73 - $90.69 $509,658 - $618,505	6,820 New	6,820 $515,000
Q2 2020 Aug 14, 2020	SELL	$79.55 - $124.22 $725,496 - $1.13 Million	-9,120 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$71.37 - $96.85 $990,615 - $1.34 Million	-13,880 Reduced 60.35%	9,120 $771,000
Q4 2019 Feb 14, 2020	BUY	$64.27 - $86.37 $12,854 - $17,274	200 Added 0.88%	23,000 $1.95 Million
Q3 2019 Nov 12, 2019	SELL	$67.4 - $85.11 $303,300 - $382,995	-4,500 Reduced 16.48%	22,800 $1.54 Million
Q2 2019 Aug 14, 2019	SELL	$80.35 - $93.9 $490,134 - $572,790	-6,100 Reduced 18.26%	27,300 $2.34 Million
Q1 2019 May 15, 2019	BUY	$84.2 - $98.62 $1.94 Million - $2.27 Million	23,000 Added 221.15%	33,400 $2.97 Million
Q4 2018 Feb 15, 2019	BUY	$80.14 - $106.07 $833,456 - $1.1 Million	10,400 New	10,400 $886,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Worth Venture Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Worth Venture Partners, LLC with notifications on news.